Endothelial Interleukin-6 Defines the Tumorigenic Potential of Primary Human Cancer Stem Cells


Key Words. Perivascular niche • Self-renewal • Survival • Squamous cell carcinoma • Angiogenesis

ABSTRACT

Head and neck squamous cell carcinomas (HNSCC) contain a small subpopulation of stem cells endowed with unique capacity to generate tumors. These cancer stem cells (CSC) are localized in perivascular niches and rely on crosstalk with endothelial cells for survival and self-renewal, but the mechanisms involved are unknown. Here, we report that stromal interleukin (IL)–6 defines the tumorigenic capacity of CSC sorted from primary human HNSCC and transplanted into mice. In search for the cellular source of Interleukin-6 (IL-6), we observed a direct correlation between IL-6 levels in tumor-associated endothelial cells and the tumorigenicity of CSC. In vitro, endothelial cell–IL-6 enhanced orosphere formation, p-STAT3 activation, survival, and self-renewal of human CSC. Notably, a humanized anti-IL-6R antibody (tocilizumab) inhibited primary human CSC-mediated tumor initiation. Collectively, these data demonstrate that endothelial cell-secreted IL-6 defines the tumorigenic potential of CSC, and suggest that HNSCC patients might benefit from therapeutic inhibition of IL-6/IL-6R signaling. Stem Cells 2014;32:2845–2857

INTRODUCTION

Head and neck squamous cell carcinomas (HNSCC) contain a small population of highly tumorigenic cells that exhibit self-renewal and multipotency, hallmarks of stem cells [1, 2]. Emerging evidence from HNSCC and other tumor types suggests that cancer stem cells (CSC) exhibit resistance to chemotherapy and radiotherapy and might be involved in the establishment of metastasis, which is a major cause of cancer-related deaths [3–5]. Such findings led to the hypothesis that improvements in the long-term outcome of patients with cancer will require ablation of CSC. CSC and physiological stem cells share similar characteristics, such as differentiation and self-renewal [6, 7]. Therefore, direct targeting of CSC might be accompanied by toxicities related to the unintended elimination of normal stem cells (e.g., hematopoietic stem cells). We recently demonstrated that CSC reside in perivascular niches in patients with HNSCC, and that endothelial cells contribute to the survival and self-renewal of CSC [8]. Importantly, CSC depend on crosstalk with tumor-associated endothelial cells for their survival and maintenance of an undifferentiated state [8], which may also contribute to tumor dormancy [9]. These discoveries raise the exciting possibility that cancer patients may benefit from the therapeutic blockade of the crosstalk between endothelial cells and CSC within the perivascular niche.

Both, physiological and CSC, depend on their microenvironment for survival and proliferation [6, 7, 10]. The protective function of the crosstalk among cells within the perivascular niche has been identified in neural stem cells [11] and neural tumors [12]. The observation that CSC reside in perivascular niches in HNSCC [8] suggests that potent antiangiogenic drugs may have a therapeutic effect on both, the endothelial cells and the CSC. However, emerging evidence demonstrated that certain antiangiogenic therapies might lead to the development of evasive resistance by enhancing the invasive phenotype of tumor cells [13–15]. These studies suggest that patients may benefit from a targeted approach that blocks signaling pathways initiated by endothelial cells and that contribute to CSC survival and self-renewal. However, the mechanisms involving the crosstalk between endothelial cells and CSC are unknown, leaving these targets unidentified.

Independent studies have shown a strong correlation between high serum Interleukin-6 (IL-6) levels and poor survival of patients with head and neck cancer [16, 17]. These studies have proposed the use of serum IL-6 as a biomarker to predict tumor recurrence and patient survival. IL-6 activates its downstream...
target signal transducer and activator of transcription 3 (STAT3), which is constitutively active in several malignancies including those of the head and neck [18]. Indeed, therapeutic inhibition of STAT3 has been found to slow down tumor growth [19, 20]. Interestingly, IL-6 plays a critical role in the biology of CSC in breast and brain tumors [21–23]. It is known that endothelial cells secrete high levels of IL-6, especially in response to inflammatory stimuli [24], which play a major role in the pathobiology of most epithelial pathologies. It has also been shown that the IL-6 receptors (IL-6R, gp130) exhibit aberrant expression patterns in some CSC, such as gliomas [22]. However, the role of IL-6 signaling in the crosstalk between endothelial cells and CSC remains unknown.

Here, we unveiled a paracrine signaling pathway initiated by IL-6 secreted by endothelial cells that enhances the survival, self-renewal, and tumorigenic potential of primary human head and neck cancer stem-like cells. Using laser capture microdissection (LCM), we determined that IL-6 expression is higher in the endothelial cells than in the tumor cells of primary human HNSCC, providing strong clinical rationale for this study. Notably, we observed that endothelial cell-secreted IL-6 enhances the tumorigenic potential and the survival of cancer stem-like cells using a series of complementary approaches that included transplantation of primary human head and neck cancer stem-like cells (ALDHHIGHCD44HIGH) into athymic IL-6−/− mice, generation of xenograft tumors with ALDHHIGHCD44HIGH cells that are vascularized with human endothelial cells stably transduced with shRNA-IL-6, and treatment of mice bearing tumors generated with ALDHHIGHCD44HIGH cells with an anti-IL-6R antibody (tocilizumab). Collectively, these data demonstrate that endothelial IL-6 contributes to the biology of CSC and suggest that therapeutic inhibition of this pathway would be beneficial for patients with head and neck cancer.

**Materials and Methods**

**Head and Neck Cancer Stem-Like Cell Sorting**

The use of primary human tumor specimens was done under protocols approved by the University of Michigan Institutional Review Board. Tumors were cut and minced with a sterile scalpel until they could pass through a 25 ml pipette tip. They were mixed in a 9:1 solution of Dulbecco’s modified Eagle’s medium (DMEM)-F-12 (Hyclone, Waltham, MA. www.thermoscientific.com) and Collagenase/Hyaluronidase (Stem Cell Technologies, Vancouver, BC, Canada. www.stemcell.com). This mixture was then incubated at 37°C for 1 hour and passed through a 10-ml pipette every 15 minutes for mechanical dissociation. Cells were filtered through a 40-μm nylon sieve (BD Falcon, BD Biosciences, Franklin Lakes, NJ. www.bdbiosciences.com), washed with low glucose DMEM, and centrifuged at 800 rpm for 3 minutes. Single-cell suspensions obtained from primary specimens (as well as from cell lines or xenografts) were washed, counted, and resuspended at 1 × 10^6 cells per milliliter PBS. The Aldefluor kit (Stem Cell Technologies, Vancouver, BC, Canada.) was used to identify cells with high ALDH activity. Briefly, cells were suspended in activated Aldefluor substrate BODipy-aminoacetate (BAA) or in a specific ALDH inhibitor diethylaminobenzaldehyde (DEAB) for 45 minutes at 37°C. Then, cells were exposed to anti-CD44 (clone G44-26BD; Pharmingen, BD Biosciences, Franklin Lakes, NJ). A series of lineage markers (i.e., anti-CD2, CD3, CD10, CD16, CD18, and CD31; BD Pharmingen) was used to eliminate lineage cells, mouse cells were eliminated using anti-H2K^d^ antibody (BD Biosciences, Franklin Lakes, NJ. www.bdbiosciences.com), and 7-Aminoactinomycin (BD Pharmingen) was used to eliminate nonviable cells. Here and throughout this manuscript, in vitro studies were done in at least triplicate specimens per condition, and three independent experiments were performed to verify reproducibility of the data.

**Orosphere Assay**

Nonadherent spheroids of head and neck cancer cells (named orospheres) were generated from fluorescence-activated cell-sorted cells (5 × 10^3 cells/well) cultured in triplicate wells in ultra-low attachment plates (Corning, NY. www.corning.com), as we showed [25]. Briefly, cells were cultured in low glucose DMEM containing or not 24-hour conditioned medium (CM) from primary human dermal microvascular endothelial cells (HDMEC, Lonza, Indianapolis, Indiana. www.lonz.com) collected in serum-free endothelial basal medium (Lonza) at a ratio of 3:1. Alternatively, cells were treated with HDMEC CM containing 0.4 μg/ml anti-IL-6 antibody (R&D Systems, Minneapolis, MN. www.rndsystems.com), 10 μg/ml humanized anti-IL-6R antibody (Tocilizumab, Chugai Pharmaceuticals, Tokyo, Japan. www.chugai-pharm.co.jp), or nonspecific isotype-matched IgG. As a positive control, we used 20 ng/ml rhIL-6 (R&D Systems). After 3 days, orospheres (defined as colonies of ≥25 cells) were visualized and quantified under light microscopy.

**Severe Combined Immunodeficient Mouse Model of Human Tumor Angiogenesis**

Xenograft tumors vascularized with functional human microvessels were generated in severe combined immunodeficient (SCID) mice (CB17 SCID; Taconic, Hudson, NY. www.taconic.com), as we described [26]. Briefly, 0–1,000 head and neck cancer stem-like cells (ALDHHIGHCD44HIGH) or 1,000 non-CSC (ALDHLowCD44High) cells were subcutaneously implanted in the dorsum of each mouse. Alternatively, mice received scaffolds containing 5 × 10^5 HDMEC-shRNA-IL-6 or HDMEC-shRNA-C in poly(L-lactic) acid biodegradable scaffolds. Bilateral scaffolds were placed subcutaneously in the dorsum of each mouse. Alternatively, mice received scaffolds containing 5 × 10^5 HDMEC cells and 1 × 10^3 ALDHHIGHCD44HIGH or ALDHLowCD44LOW cells. Starting on Day 1, mice received weekly intraperitoneal injections of either 10 mg/kg humanized anti-IL-6 antibody (Chugai Pharmaceuticals) or nonspecific IgG, as described [27]. After 30 days, mice were euthanized and tumors were retrieved, measured, weighed, and processed. The impact of host IL-6 on tumor initiation was evaluated in C57B6 IL-6−/− and IL-6+/+ mice [28] originally purchased from the Jackson Laboratories, and backcrossed onto an immunodeficient/athymic mouse background.

**Results**

**Stromal IL-6 Enhances the Survival of Cancer Stem-Like Cells**

Serum IL-6 has been identified as an independent predictor of poor survival in head and neck squamous cell carcinoma patients [17]. It is known that IL-6 is a potent inflammatory cytokine secreted by stromal cells, and that IL-6 enhances stem cell properties in gliomas [22]. However, the mechanisms underlying the effect of endothelial cell-secreted IL-6
on the biology of HNSCC are unknown. To begin to understand the impact of stromal IL-6 on the survival of CSC, we generated tumor xenografts by transplanting primary human cancer stem-like cells (ALDH\textsuperscript{HIGH}CD44\textsuperscript{HIGH}) in IL-6\textsuperscript{+/+} athymic mice (Fig. 1A). For this, immediately after surgical removal of the primary tumor from patients with HNSCC (Supporting Information Fig. S1), cancer stem-like cells (i.e., ALDH\textsuperscript{HIGH}CD44\textsuperscript{HIGH}) were sorted and transplanted in IL-6\textsuperscript{+/+} immunodeficient mice. 1,000 ALDH\textsuperscript{HIGH}CD44\textsuperscript{HIGH} cells transplanted in IL-6\textsuperscript{+/+} mice generated more and larger tumors than transplantation of 1,000 ALDH\textsuperscript{HIGH}CD44\textsuperscript{HIGH} into IL-6\textsuperscript{−/−} immunodeficient mice. (C): Graph depicting the percentage of cancer stem-like cells in tumor xenografts, as compared to the primary tumor. (D): RT-PCR showing the mRNA expression of IL-6 in human endothelial cells as compared to the tumor cells. Cells were retrieved by LCM from paraffin-embedded sections from four different patients with primary HNSCC. (E): Confocal microscopy of a primary human HNSCC immunostained for ALDH1 (green) and IL-6R (red). DAPI (blue) identified nuclei (Patient 19). (F): Western Blot for IL-6R and gp130 in head and neck cancer stem-like cells (ALDH\textsuperscript{HIGH}CD44\textsuperscript{HIGH}) and control cells (ALDH\textsuperscript{LOW}CD44\textsuperscript{LOW}) sorted from two HNSCC cell lines (UM-SCC-74A, UM-SCC-74B). Abbreviations: FACS, fluorescence-activated cell sorting; HNSCC, head and neck squamous cell carcinomas; IL-6, interleukin-6; LCM, laser capture microdissection.

Figure 1. Stromal IL-6 supports the survival of cancer stem-like cells. (A): Schematic representation of the approach used for testing the role of stromal IL-6 on the tumorigenic potential of cancer stem-like cells (ALDH\textsuperscript{HIGH}CD44\textsuperscript{HIGH}) in primary tumors. ALDH\textsuperscript{HIGH}CD44\textsuperscript{HIGH} cells were isolated from primary human HNSCC and implanted in IL-6\textsuperscript{−/−} or IL-6\textsuperscript{+/+} immunodeficient mice. At the termination of the experiment, tumors were retrieved, single-cell suspensions prepared, and the proportion of ALDH\textsuperscript{HIGH}CD44\textsuperscript{HIGH} cells determined by FACS. (B): Graph represents the volume of tumors arising from primary human ALDH\textsuperscript{HIGH}CD44\textsuperscript{HIGH} cells transplanted into IL-6\textsuperscript{−/−} or IL-6\textsuperscript{+/+} immunodeficient mice. (C): Graph depicting the percentage of cancer stem-like cells in tumor xenografts, as compared to the primary tumor. (D): RT-PCR showing the mRNA expression of IL-6 in human endothelial cells as compared to the tumor cells. Cells were retrieved by LCM from paraffin-embedded sections from four different patients with primary HNSCC. (E): Confocal microscopy of a primary human HNSCC immunostained for ALDH1 (green) and IL-6R (red). DAPI (blue) identified nuclei (Patient 19). (F): Western Blot for IL-6R and gp130 in head and neck cancer stem-like cells (ALDH\textsuperscript{HIGH}CD44\textsuperscript{HIGH}) and control cells (ALDH\textsuperscript{LOW}CD44\textsuperscript{LOW}) sorted from two HNSCC cell lines (UM-SCC-74A, UM-SCC-74B). Abbreviations: FACS, fluorescence-activated cell sorting; HNSCC, head and neck squamous cell carcinomas; IL-6, interleukin-6; LCM, laser capture microdissection.
LCM of endothelial cells or carcinoma cells from several head and neck cancer patients [29] and observed that IL-6 expression was significantly higher in the endothelial cells than in the tumor cells (Fig. 1D). These data were corroborated by the observation that human endothelial cells secrete more IL-6 than HNSCC cell lines (p < .05) (Supporting Information Fig. S2A, S2B). Confocal microscopy from human HNSCC tissue sections revealed colocalization of ALDH and IL-6R (Fig. 1E). Western blots showed that ALDH<sub>HIGH</sub>CD44<sub>HIGH</sub> cells express higher levels of IL-6R than control ALDH<sub>LOW</sub>CD44<sub>LOW</sub> cells, while the expression of gp130 was similar (Fig. 1F). Collectively, these data demonstrated that the elements required for an IL-6-mediated crosstalk within the perivascular stem cell niche are in place in human head and neck tumors.

**Endothelial Cell-Secreted IL-6 Enhances the Survival of Cancer Stem-Like Cells and Promotes Tumor Initiation**

To evaluate the impact of endothelial cell-secreted IL-6 on the biology of cancer stem-like cells, we silenced its expression in primary human dermal microvascular endothelial cells.
(HDMEC) and used these cells to generate tumor xenografts with a humanized vasculature, as we described [26]. In an attempt to verify the specificity of lentiviral-mediated IL-6 silencing in primary endothelial cells, we observed a significant inhibition of IL-6 expression, but no significant change in expression of IL-8 (Supporting Information Fig. S2C). Using this approach, we have shown that the vast majority of the blood vessels within the xenograft tumors are lined with the human endothelial cells that were transplanted in the scaffold [26]. We observed that xenograft tumors vascularized with IL-6-silenced endothelial cells exhibited similar microvessel density as those vascularized with endothelial cells transduced with empty lentiviral vectors (p = .117). The tumor cells used here were primary human cancer stem-like (ALDHHIGHCD44-HIGH) cells sorted from three different patients with HNSCC (Fig. 2A–2D). Time to palpability was used as a determinant of the tumorigenic potential of the cell combinations tested here. We observed that transplantation of 1,000 ALDHHIGHCD44-HIGH cells generated tumors in 100% of the mice (n = 26) within 38 days (Fig. 2B). However, cotransplantation of HDMEC-shRNA-IL-6 with ALDHHIGHCD44-HIGH significantly delayed (p = .0016) the time to tumor palpability as compared to cotransplantation of scrambled sequence control endothelial cells and ALDHHIGHCD44-HIGH (Fig. 2B). When individual tumors are tracked, one observes an overall trend for earlier initiation and larger volumes of tumors vascularized with HDMEC-shRNA-C than in tumors vascularized with HDMEC-shRNA-IL-6 cells (Fig. 2C). Notably, the average volume was smaller when endothelial cells stably transduced with shRNA-IL-6 were used to vascularize the xenograft tumors generated with cancer stem-like cells sorted from three different patients, demonstrating that this effect was not patient-specific (Fig. 2D).

To more rigorously study the effect of endothelial cell-secreted IL-6 on tumor initiation, we performed a serial dilution experiment. We implanted 1,000, 100, 10, or 0 ALDHHIGHCD44-HIGH cells sorted from a primary human HNSCC along with either HDMEC-shRNA-C or HDMEC-shRNA-IL-6 cells. We observed that cotransplantation of HDMEC-shRNA-IL-6 with ALDHHIGHCD44-HIGH significantly delayed (p = .0004) tumor initiation as compared to cotransplantation of control endothelial cells and ALDHHIGHCD44-HIGH (Fig. 2E), confirming the data discussed above (Fig. 2B). Notably, all implants containing at least 10 ALDHHIGHCD44-HIGH cells generated tumors (Fig. 2F). However, the larger the number of cancer stem-like cells, the shorter the time to palpability (Fig. 2F). A pair-wise statistical comparison between different ALDHHIGHCD44-HIGH cell densities demonstrated that the greater the initial number of cancer stem-like cells, the greater the effect of endothelial cell-secreted IL-6 in promoting tumors (Fig. 2G). Together, these studies demonstrate that endothelial cell-secreted IL-6 enhances the tumorigenic potential of cancer stem-like cells in vivo.

The density (fraction) of CSC in a tumor is considered indicative of poor prognosis for cancer patients [30]. To evaluate the effects of endothelial cell-secreted IL-6 on the fraction of cancer stem-like cells in vivo, we evaluated the percentage of ALDHHIGHCD44-HIGH cells in xenograft tumors generated with cancer stem-like cells retrieved from primary human HNSCC (Fig. 2A). Ablation of endothelial cell-secreted IL-6 within the tumor microenvironment resulted in a significant decrease in the proportion of cancer stem-like cells (p = .041), as compared to xenografts vascularized with control endothelial cells from cancer stem-like cells from primary patients (Fig. 3A). To confirm the studies performed with cells sorted from primary human HNSCC, we repeated these analyses with cells sorted from a well-characterized human HNSCC cell line (UM-SCC-74A). We observed that the fraction of cancer stem-like cells was significantly reduced (p = .010) and the tumor initiation in xenografts was delayed (p = .0008) when xenografts were vascularized with IL-6-silenced human endothelial cells (Fig. 3B, 3C). Notably, the tumor microvascular density was not affected by the silencing of IL-6 in the endothelial cells, as determined by sorting these xenograft tumors for the endothelial marker CD31 (Supporting Information Fig. S2D).

Endothelial Cell-Secreted IL-6 Promotes CSC Properties In Vitro

To evaluate the functional role of endothelial cell-secreted IL-6 on cancer stem-like cells in vitro, we exposed unsorted head and neck cancer cells (UM-SCC-74A) to endothelial cell CM in presence of a neutralizing antibody to IL-6 and measured the percentage of ALDHHIGHCD44-HIGH by flow cytometry (Fig. 3D). Endothelial cell CM increased the fraction of cancer stem-like cells (Fig. 3D, 3E). However, treatment of the CM with anti-IL-6 antibody reduced the percentage of cancer stem-like cells back to baseline levels (Fig. 3E), without a significant effect in overall cell survival (data not shown). To evaluate the effect of endothelial cell-secreted IL-6 on the

Figure 2. Endothelial cell-secreted IL-6 enhances the tumorigenic potential of cancer stem-like cells. (A): Schematic representation of the approach used for testing the role of endothelial cell-secreted IL-6 on the tumorigenic potential of primary human ALDHHIGHCD44-HIGH cells. ALDHHIGHCD44-HIGH cells were sorted from primary HNSCC and implanted in immunodeficient mice to generate xenograft tumors vascularized with HDMEC-shRNA-IL-6 or control HDMEC-shRNA-C. (B): Graph showing the percentage of palpable tumors over time in ALDHHIGHCD44-HIGH tumors vascularized with HDMEC-shRNA-IL-6 or HDMEC-shRNA-C. (C): Graph showing individual tumor volume over time (n = 13). Photomicrographs (>200) of HE-stained tissue sections of scaffolds containing 1,000 primary human ALDHHIGHCD44-HIGH cells and vascularized with HDMEC-shRNA-IL-6 or HDMEC-shRNA-C, 30 days after implantation in severe combined immunodeficient mice. Few (if any) tumor cells are visible in the implants vascularized with HDMEC-shRNA-IL-6, while the entire microscopically field is populated with tumor cells in the implants vascularized with HDMEC-shRNA-C. The PLLA scaffold (white areas) is still visible in the implants containing ALDHHIGHCD44-HIGH/HDMEC-shRNA-IL-6, while in the implants containing ALDHHIGHCD44-HIGH/HDMEC-shRNA-C group the scaffold has already been completely resorbed by the enzymatic activity of the tumor cells. (D): Graph showing the average tumor volume of tumor xenografts generated by cells sorted from HNSCC from three patients at Day 45 (p < .05). (E–G): ALDHHIGHCD44-HIGH cells were isolated from a primary HNSCC (Patient 26) and implanted in serial dilutions of 1,000, 100, 10, or 0 cells along with 500,000 HDMEC-shRNA-IL-6 or HDMEC-shRNA-C cells in immunodeficient mice. (E): Graph showing the overall trend for time to palpability. In this case, the zero ALDHHIGHCD44-HIGH cell group was not included, as no tumors were observed in this experimental condition. (F): Graph showing the percentage of palpable tumors over time for each individual experimental condition. (G): Table showing the pairwise statistics for the experimental conditions that generated tumors, as determined using the Bonferroni correction at p < .0125. Abbreviations: HDMEC, human dermal microvascular endothelial cells; HNSCC, head and neck squamous cell carcinomas; IL-6, interleukin-6.
survival and self-renewal of cancer cells, we plated ALDH\textsuperscript{HIGH}CD44\textsuperscript{HIGH} or ALDH\textsuperscript{LOW}CD44\textsuperscript{LOW} cells in ultra-low attachment plates and evaluated the formation of nonadherent colonies of cells (named orospheres). As expected, more orospheres were generated by ALDH\textsuperscript{HIGH}CD44\textsuperscript{HIGH} cells than from ALDH\textsuperscript{LOW}CD44\textsuperscript{LOW} cells, and the number of orospheres was increased upon treatment with endothelial cell CM (Fig. 3F; Supporting Information Fig. S3), confirming our previous report [8]. Notably, neutralizing anti-IL-6 antibody inhibited the inductive effect of endothelial cell CM, while rhIL-6 increased the number of orospheres (but not to the same extent as the CM). To ascertain that the orospheres were not formed simply by cell aggregation, we also performed single-cell colony formation assays in ultra-low attachment plates (Fig. 3G). We observed that endothelial cell CM increased the number of orospheres as compared to controls, and that an anti-IL-6 neutralizing antibody blocked this effect.

To verify the data obtained with anti-IL-6 antibody, we used a second approach consisted of treating unsorted tumor cells with CM from the HDMEC-shRNA-IL-6 or HDMEC-C cells...
had been postulated that CSC exhibit an invasive phenotype, which could be involved in the generation of secondary tumors [31]. Considering the fact that human HNSCC are highly invasive, we evaluated the effects of endothelial cell-secreted IL-6 on the invasive phenotype of ALDH\textsuperscript{HIGH}CD44\textsuperscript{HIGH} cells in vitro. We observed that CM from endothelial cells significantly enhanced the invasive potential of ALDH\textsuperscript{HIGH}CD44\textsuperscript{HIGH} cells (Supporting Information Fig. S4A, S4B).

Taken together, these findings demonstrate that endothelial cells constitute a critical source of the IL-6 that promotes the survival, self-renewal, and invasive potential of head and neck cancer stem-like cells in vitro.

### Endothelial Cell-Secreted IL-6 Induces STAT3 Phosphorylation in CSC

The canonical IL-6 signal transduction pathway involves binding to IL-6R and to the common signal transducing receptor gp130, signaling through the Janus kinases, and activation of STAT3. Activation of STAT3 signaling plays an important role in the self-renewal and stemness of embryonic stem cells, intestinal stem cells, and glioblastoma stem cells [23, 32–34]. Therefore, phosphorylation of STAT3 might be considered indicative of stemness. Immunohistochemical examination of primary HNSCC tissues showed strong expression of p-STAT3 around tumor blood vessels (Fig. 4A), where most human HNSCC cancer stem-like cells are located. To evaluate the expression pattern of p-STAT3 in cancer stem-like cells, we sorted cells from a primary HNSCC and observed that ALDH\textsuperscript{HIGH}CD44\textsuperscript{HIGH} cells exhibit constitutive phosphorylation of STAT3 while the non-stem cell population (ALDH\textsuperscript{LOW}CD44\textsuperscript{LOW}) did not (Fig. 4B). It is known that the activation of the ERK-MAPK pathway correlates with the loss of stemness and acquisition of a more differentiated state [35, 36]. Here, we observed that cancer stem-like cells (ALDH\textsuperscript{HIGH}CD44\textsuperscript{HIGH}) showed low expression of p-ERK, while ALDH\textsuperscript{LOW}CD44\textsuperscript{LOW} cells exhibited constitutive activation of this pathway (Fig. 4B).

Graph depicting the number of orospheres arising from ALDHHIGHCD44HIGH cells sorted from primary HNSCC (Fig. 4B).

To evaluate the impact of endothelial cell-secreted factors on the activation of STAT3, we exposed ALDHHIGHCD44HIGH cells to endothelial cell CM and analyzed the phosphorylation levels of STAT3 over time. We found that endothelial cell CM enhanced STAT3 phosphorylation in ALDHHIGHCD44HIGH cells in a time-dependent manner (Fig. 4C). Blockade of IL-6 with neutralizing antibodies abrogated the inductive effect of endothelial cells on STAT3 phosphorylation (Fig. 4D). Likewise, exposure of cancer stem-like cells to CM from IL-6-silenced endothelial cells did not induce STAT3 phosphorylation beyond baseline levels (Fig. 4E).

The number of orospheres induced by endothelial cell CM was also smaller in IL-6R-silenced tumor cells, as compared to controls (Fig. 4H). Collectively, these data demonstrated that IL-6 secreted by endothelial cells signals through IL-6R to activate STAT3 signaling, which functions as a critical regulator of the self-renewal and survival of head and neck CSC.

### Humanized Anti-IL-6R Antibody Inhibits the Survival of Cancer Stem-Like Cells and Delays Tumor Initiation

To enhance the translational significance of this work, we performed a series of experiments with the humanized anti-human IL-6R antibody tocilizumab developed by Chugai/Roche [27]. This antibody was approved by the FDA for the treatment of rheumatoid arthritis in 2010. Tocilizumab blocked the effect of endothelial cell CM on the generation of orospheres with cells sorted from primary HNSCC (Fig. 5A) and inhibited endothelial cell-induced phosphorylation of STAT3 in vitro (Fig. 5B). To test the efficacy of inhibition of IL-6R signaling on tumor initiation, we implanted ALDHHIGHCD44HIGH or ALDHLowCD44low cells sorted from a primary HNSCC and treated the mice with tocilizumab (or IgG controls) for 4 weeks.

**Summary:**

Endothelial cell-secreted IL-6 promotes the survival and self-renewal of cancer stem-like cells. Endothelial cells secrete IL-6, which activates STAT3. Neutralizing antibodies against IL-6 prevent STAT3 phosphorylation. Tocilizumab, an anti-IL-6R antibody, inhibits STAT3 phosphorylation and delays tumor initiation.
Figure 4. Endothelial cell-secreted IL-6 activates the STAT3 pathway in head and neck cancer stem-like cells. (A): Immunohistochemical localization of ALDH1-positive and p-STAT3-positive cells in tumor xenografts generated with ALDH<sup>HIGH</sup>CD44<sup>HIGH</sup> cells sorted from primary human HNSCC. (B): Western blot showing baseline phosphorylation of STAT3 and ERK in head and neck cancer stem-like cells (ALDH<sup>HIGH</sup>CD44<sup>HIGH</sup>) compared to control cells (ALDH<sup>LOW</sup>CD44<sup>LOW</sup>) sorted from a primary HNSCC (Patient 28) or from a head and neck cancer cell line (UM-SCC-74A). (C): Western blot for phosphorylated and total STAT3 in ALDH<sup>HIGH</sup>CD44<sup>HIGH</sup> cells cultured in ultra-low attachment plates and treated with endothelial cell CM for 0–24 hours. (D): Western blots for phosphorylated and total STAT3 in ALDH<sup>HIGH</sup>CD44<sup>HIGH</sup> or ALDH<sup>LOW</sup>CD44<sup>LOW</sup> cells treated with endothelial cell CM in presence of anti-IL-6 antibody or IgG for 15 minutes. (E): Western blots for phosphorylated and total STAT3 in ALDH<sup>HIGH</sup>CD44<sup>HIGH</sup> or ALDH<sup>LOW</sup>CD44<sup>LOW</sup> cells treated with CM collected from HDMEC-shRNA-IL-6 or control HDMEC-shRNA-C for 30 minutes. (F): Western blot to determine the effectiveness of IL-6R knockdown in UM-SCC-74A cells (shRNA-IL-6R); and STAT3 knockdown in UM-SCC-74B cells (shRNA-STAT3). We used three different shRNA sequences and determined that sequence c was the most effective to downregulate STAT3 expression. As controls, we transduced cells with a scrambled sequence (shRNA-C). (G): Western blots for phosphorylated and total STAT3 in UM-SCC-74A cells transduced with shRNA-IL-6R (or control shRNA-C) and exposed to endothelial cell conditioned medium for 0–60 minutes. (H): Graph depicting the number of orospheres arising from UM-SCC-74A cells stably transduced with shRNA-IL-6R and cultured in ultra-low attachment plates. All cells were cultured in presence of 24-hour EC CM. The untreated control for these experiments was serum-free endothelial basal (EBM) medium. (I): Graph depicting the number of orospheres arising from UM-SCC-74B cells stably transduced with shRNA-STAT3(c) or shRNA-C and cultured in ultra-low attachment plates. Cells were cultured in presence (or absence) of 20 ng/ml rhIL-6. The untreated control for this experiment was serum-free EBM supplemented with PBS (vehicle for rhIL-6). Different lower case letters represent p < .05. Abbreviations: EC CM, endothelial cell conditioned medium; HNSCC, head and neck squamous cell carcinomas; IL-6, interleukin-6.
Figure 5. A humanized anti-human IL-6R antibody (tocilizumab) inhibits self-renewal and tumor initiation of human head and neck cancer stem-like cells transplanted in mice. (A): Graph represents the relative number of orospheres arising from ALDHHIGHCD44HIGH and ALDHLowCD44Low cells cultured in ultra-low attachment plates with endothelial cell CM in presence of 0 or 10 μg/ml anti-IL-6R antibody. (B): Western blot showing the phosphorylation of STAT3 in ALDHHIGHCD44HIGH and ALDHLowCD44Low cells cultured in ultra-low attachment plates with endothelial cell CM in presence of 0 or 10 μg/ml anti-IL-6R antibody. (C): Schematic representation of the experimental design. Tumor xenografts were generated by the implantation of 1,000 ALDHHIGHCD44HIGH or ALDHLowCD44Low cells sorted from a primary human HNSCC (Patient 34) along with 5 × 10^5 primary endothelial cells (HDMEC). Mice received weekly intraperitoneal injections of 10 mg/kg anti-IL-6R antibody or IgG for 4 weeks. (D, E): Kaplan-Meier analysis showing the percentage of palpable tumors over time (D). Palpable tumor is defined as tissue overgrowth beyond the size of the scaffold used for cell transplantation. Tumors were only observed upon transplantation of ALDHHIGHCD44HIGH cells, that is, six tumors out of six transplants in the IgG-treated group, and one tumor out of six transplants in the IL-6R antibody-treated group. None of the scaffolds transplanted with ALDHLowCD44Low cells generated a tumor. (E): Graph showing the tumor volume 30 days after transplantation. Please note that the volume of the scaffold by itself (without palpable tumor) measured through the skin is typically 70–100 mm^3. (F): Graph depicting the percentage of ALDHHIGHCD44HIGH cells at the end of the experimental period (16 weeks). Different lower case letters represent p < .05. Abbreviations: EC CM, endothelial cell conditioned medium; HDMEC, human dermal microvascular endothelial cells; HNSCC, head and neck squamous cell carcinomas; IL-6, interleukin-6.
observed a significant reduction in the proportion of CSC compared to mice from the IgG control group (Fig. 5F). As expected, none of the mice (0/12) transplanted with control ALDH<sup>LOW</sup>CD44<sup>LOW</sup> cells developed tumors within the experimental time (Fig. 5D). The average tumor volume of the mice in the IgG group was significantly higher than in the tocilizumab-treated group (Fig. 5E). Importantly, we observed a significant reduction in the proportion of CSC (ALDH<sup>HIGH</sup>CD44<sup>HIGH</sup> cells) in mice treated with tocilizumab, as compared to mice from the IgG control group (Fig. 5F).

To more fully understand the effect of the anti-IL-6R antibody tocilizumab on the fraction of CSC, we performed a long-term in vivo of 4 months (Fig. 5G). In this case, we generated xenograft tumors with ALDH<sup>HIGH</sup>CD44<sup>HIGH</sup> cells sorted from UM-SCC-74B and administered weekly anti-IL-6R antibody for 16 weeks or for 4 weeks followed by 12 weeks without antibody. We observed that treatment with the anti-IL-6R antibody resulted in a smaller fraction of ALDH<sup>HIGH</sup>CD44<sup>HIGH</sup> cells in this tumor model. Surprisingly, this effect was maintained in the group without antibody for the last 12 weeks, suggesting that the effect of IL-6 signaling blockade on head and neck CSC is long lasting.

**DISCUSSION**

Acquired resistance to therapy is a major challenge in the management of patients with head and neck cancer. Platinum-based drugs have substantially improved the control of locoregional disease [37]. However, with improved local control of the disease with enhanced radiation therapy, concurrent chemotherapy, and advanced surgical techniques, distant metastasis has become a larger percentage of failures in patients with oral cancer [38]. As a consequence, the survival of patients with HNSCC remained largely unchanged over the last 35 years [39]. The poor survival and high recurrence/metastasis rates in patients with HNSCC can possibly be explained by the CSC hypothesis where the regeneration of a tumor (or the establishment of metastatic foci) requires at least one CSC. Notably, CSC are believed to be resistant to conventional chemotherapeutic drugs, exhibit an invasive phenotype, and resist anokia or death by anchorage independence. These characteristics make CSC prime candidates to drive the process of recurrence and metastasis frequently observed in patients with head and neck cancer. Here, we performed a series of complementary studies to understand mechanisms used by primary human head and neck CSC to survive while retaining an undifferentiated and highly tumorigenic phenotype.

We have previously demonstrated that the combination of high ALDH activity and high CD44 expression discriminates a small subpopulation of highly tumorigenic cells that have the features of CSC in HNSCC [8]. We found that these cells exist in perivascular niches and that endothelial cell-secreted factors enhanced the survival of the CSC, but the critical mediators of this crosstalk were unclear. The importance of stromal IL-6 on tumor initiation and tumor growth was demonstrated in this study by experiments with xenografts generated with stem-like cells sorted from primary human HNSCC and implanted in immunodeficient IL-6−/− or IL-6+/− mice. We observed a 10-fold decrease in the proportion of cancer stem-like cells in tumors generated in the IL-6−/− mice. These results demonstrated that host-derived IL-6 plays an important role in the survival/self-renewal of CSC. Ongoing studies attempt to determine whether this effect was mediated by a direct interaction of the host IL-6 with the cancer stem-like cells, or indirectly by modulating the inflammatory response. Here, our focus was directed to the endothelial cells as a source of the stromal IL-6 for the following reasons: (a) We observed that endothelial cells express high IL-6 levels in human HNSCC; (b) IL-6 is upregulated under inflammatory conditions [24], which are typically observed in HNSCC; and (c) CSC exhibit perivascular localization in the head and neck tumor microenvironment.

We observed that endothelial-secreted IL-6 enhances the survival and the stem cell properties of head and neck cancer cells. Interestingly, IL-6 is secreted from thymic blood vessels in response to therapy and promotes the survival of doxorubicin-resistant cells in Burkitt’s lymphoma [40]. One could speculate that these resistant cells exhibit stem-like properties. Furthermore, work in lung carcinomas recently showed that stromal endothelial cells contribute to tumor growth [41]. We observed here that IL-6 secreted by endothelial cells is a potent inducer of the tumor-initiating capacity of head and cancer stem-like cells. These data do not exclude the possibility that other cell types (e.g., myeloid cells) contribute to the overall levels of IL-6 in the tumor microenvironment. However, the experiments in which complementary xenograft tumor models are vascularized with IL-6-silenced endothelial cells (or controls) provide strong evidence that IL-6 secreted by the vascular endothelium is a key determinant of the fraction of CSC and the time-to-palpability of tumors. Taken together, these studies identify endothelial cell-initiated signaling events as important mediators of the tumorigenicity of CSC and suggest that such events may contribute to the development of acquired resistance to therapy.

While the concept of perivascular niche for stem cells has been described several years ago [11, 12], the understanding of the complex cell-cell interactions within the niche is still emerging. It is known that stem cells reside nearby blood vessels in many tissues, including the bone marrow, brain, and heart [42]. It is also known that endothelial cells in steady state secrete IL-6, and that IL-6 expression can be upregulated by inflammatory cytokines such as IL-1β [43]. These studies suggest that endothelial cell-secreted IL-6 may play a role in the maintenance of the stem cell pool within physiological conditions, and perhaps also during inflammation. In head and neck tumors, we observed that IL-6 secreted by endothelial cells induces survival and self-renewal of ALDH<sup>HIGH</sup>CD44<sup>HIGH</sup> cancer stem-like cells. Although we observed an increase in the number of oospheres with rhIL-6 treatment, it was not as potent as the induction mediated by complete endothelial cell CM. This suggests that other endothelial cell-secreted factors might contribute to the biology and behavior of CSC. For example, interleukin-8 (CXCL8) is a chemokine that signals through CXCR1 and CXCR2, is expressed in head and neck cancer, and has been implicated in processes that regulate the biology of CSC [44–46]. We have also recently observed that endothelial cell-secreted epidermal growth factor induces epithelial to mesenchymal transition (EMT) in head and neck cancer cells, enhancing their
Collectively, the understanding of the physiological role of IL-6 and the mechanistic studies performed here, provided the rationale for the therapeutic targeting of the IL-6 signaling pathway in HNSCC. It has been observed that the most common adverse effects of therapeutic inhibition of IL-6R in clinical studies are respiratory tract infections, headaches, and hypertension [49], which might be related to biological roles of endothelial cell-derived IL-6 in the recruitment of immune cells and regulation of vascular physiology. Furthermore, IL-6 inhibitors are currently being tested in clinical trials for cancer apart from their use in chronic inflammatory conditions. For example, the anti-IL-6 monoclonal antibody CNTO 328 (siltuximab) is in clinical trials for refractory multiple myelomas and metastatic renal cell cancer [50, 51]. Blockade of IL-6R signaling with tocilizumab inhibited xenograft tumor angiogenesis [27]. Here, we observed that tocilizumab dramatically inhibited the tumor-initiating capacity of primary human cancer stem-like cells. Notably, the fraction of cancer stem-like cells was significantly decreased in the mice treated with tocilizumab suggesting that inhibition of IL-6R signaling was sufficient to reduce the survival and/or self-renewal of head and neck cancer stem-like cells in vivo.

**CONCLUSIONS**

We have recently demonstrated that silencing of IL-6 in endothelial cells is sufficient to slowdown tumor growth in proof-of-principle experiments using a cervical adenocarcinoma model [52]. Here, we demonstrated that endothelial cell-secreted IL-6 signaling through IL-6R promotes self-renewal and survival of human primary head and neck cancer stem-like cells (Fig. 6). Blockade of this signaling pathway inhibited tumor initiation and reduced the fraction of cancer stem-like cells in existing tumors. This work establishes the crosstalk between endothelial cells and putative CSC as a critical mechanism of tumor initiation, and singles out IL-6 as an important signaling molecule in this process. Considering the fact that endothelial cells are readily accessible to systemic therapies, and the recent discovery of potent and specific inhibitors, therapeutic targeting of the IL-6 signaling pathway is emerging as a promising therapeutic strategy for patients with head and neck squamous cell carcinoma.

**ACKNOWLEDGMENTS**

We thank Amy Koh-Paige for her help with the IL-6−/− mice, Renata Licks for tissues specimens used for LCM, Chris Strayhorn for assistance with the histology, and Chris Jung for his expertise in medical illustration. We also thank the University of Michigan Flow Cytometry Core and the Imaging Core for their expertise. We thank Chugai Pharmaceutical Co. and Genentech for providing us with the humanized anti-IL-6R antibody (tocilizumab). This work was supported by Weathermax foundation, University of Michigan Comprehensive Cancer Center; Grant P50-CA-97248 (University of Michigan Head and Neck SPORE) and P01-CA093900 from the NIH/NCI; and Grants R21-DE19279 and R01-DE21139 from the NIH/NIDCR.

**AUTHOR CONTRIBUTIONS**

S.K.: participated in the design of the study, carried out in vitro and in vivo experiments, drafted the manuscript, and read and approved this manuscript; K.A.W., Z.D., A.I., and C.N.: participated in the mouse experiments and generation of cell lines and read and approved this manuscript; B.B.W., J.I.H., and M.E.P.: provided human tumor specimens, provided clinic/pathologic expertise for this work, and read and approved this manuscript; R.S.T., P.J.P., and M.S.W.: provided critical intellectual input in the design of these experiments, interpretation of the data as members of S.K.’s Ph.D. thesis committee, and read and approved this manuscript; L.K.M.: provided the immunodeficient IL-6 knockout mice and...
wild-type controls and read and approved this manuscript; E.L.B.: provided the statistical analyses of the data and read and approved this manuscript; J.E.N.: conceived the study, participated in its design and coordination, drafted the manuscript, and read and approved this manuscript.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

Max Wicha is an advisor for and has equity in OncoMed Pharmaceuticals. Jacques Nör is the Co-PI of a research grant from MedImmune.

REFERENCES


